Chronic Kidney Disease News and Research

Latest Chronic Kidney Disease News and Research

Phosphate regulating hormone associated with increased risk of kidney failure and death among CKD patients

A high level of a hormone that regulates phosphate is associated with an increased risk of kidney failure and death among chronic kidney disease (CKD) patients, according to a recent study led by researchers at the University of Miami and funded by the National Institute of Diabetes and Digestive Diseases and Kidney Diseases (NIDDK) at the National Institutes of Health.

16 Jun 2011

High FGF-23 hormone levels linked to increased risk of end-stage renal disease and death

Patients in the early stages of chronic kidney disease who had elevated levels of the endocrine hormone fibroblast growth factor 23 (that regulates phosphorus metabolism) had an associated increased risk of end-stage renal disease and death, according to a study in the June 15 issue of JAMA.

15 Jun 2011

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced it successfully completed patient enrollment in its phase II Contrast-Induced Acute Kidney Injury study with its oral drug candidate CRMD001.

14 Jun 2011

Study reveals positive impact of Soliris on long-term outcomes in PNH patients

Alexion Pharmaceuticals, Inc. today announced the presentation of research that provides further insight into the clinical consequences of paroxysmal nocturnal hemoglobinuria (PNH), and positive impact of Soliris® (eculizumab) therapy on long-term outcomes.

13 Jun 2011

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Alexion Pharmaceuticals, Inc. today announced the presentation of final data from the two Phase 2 studies of Soliris as a treatment for patients with atypical hemolytic uremic syndrome.

13 Jun 2011

Promising results from KAI-4169 program for CKD-MBD presented at ENDO 2011

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced clinical and preclinical data from its lead program, KAI-4169, at the Endocrine Society's 93rd Annual Meeting (ENDO 2011) taking place in Boston, June 4-7, 2011. KAI-4169 is a novel pharmaceutical agent being developed for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).

7 Jun 2011

Higher than IOM recommended Vitamin D levels required for optimizing osteoporosis, low BMD therapy

To fully optimize a drug therapy for osteoporosis and low bone mineral density (BMD), patients should maintain vitamin D levels above the limits recently recommended by the Institute of Medicine (IOM), according to a new study by researchers from Hospital for Special Surgery in New York. The study will be presented at the Endocrine Society's Annual Meeting in Boston, June 4-7.

7 Jun 2011

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Relypsa, Inc. today announced the presentation of positive results from a Phase 2 clinical trial of the company's lead compound, RLY5016, a non-absorbed oral potassium binder being developed as a treatment for hyperkalemia (elevated serum potassium levels).

23 May 2011

Stem cells from kidneys - World first from Australian scientists

According to Australian scientists, their latest stem cell research breakthrough will bring new treatments for a growing epidemic of chronic kidney disease. They are the first in the world to generate a type of stem cell from human kidney cells. The Melbourne scientists are hoping their discovery will have far-reaching effects in treating the disease.

19 May 2011

DaVita completes nationwide rollout of wireless Internet access at dialysis treatment clinics

DaVita Inc., a leading provider of kidney care services for those diagnosed with end stage renal disease and chronic kidney disease, today announced that every one of its clinics across the country now makes wireless Internet access available to all patients while they undergo dialysis treatments.

4 May 2011

FibroGen announces proof-of-principle for FG-4592 Phase 2 study in hemodialysis patients

FibroGen, Inc., today announced proof-of-principle for oral anemia therapy FG-4592, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, in end-stage renal disease patients receiving hemodialysis.

4 May 2011

Mediaplanet releases Kidney Health report to targeted markets in USA

On April 29, 2011, Mediaplanet Publishing released a Kidney Health report to targeted markets in USA Today. The report will be distributed to 1 million readers with contributions from Kidney Cancer Association, National Kidney Foundation, Fresenius Medical Care North America, UKidney, Medical Education Institute, and National Kidney Registry.

30 Apr 2011

DVA is now DaVita Labs

Operating as a division of DaVita Inc., a leading provider of kidney care services for those diagnosed with end stage renal disease and chronic kidney disease, DVA Laboratory Services announced its new company name, DaVita Labs.

30 Apr 2011

Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced results of additional analyses from two Phase 3 studies of the investigational agent, peginesatide in chronic renal failure patients on dialysis with anemia.

29 Apr 2011

Ramipril can effectively reduce risk of ESRD in obese patients

The angiotensin-converting enzyme inhibitor drug, ramipril, is particularly effective in lowering the risk of end-stage renal disease in obese patients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

29 Apr 2011

ACC/AHA release consensus document to help clinicians reduce risk of hypertension in older adults

Hypertension is very common among older adults. 64 percent of older men and 78 percent of older women have high blood pressure, placing them at heightened risk for heart disease including heart failure, stroke, coronary artery disease and atrial fibrillation, as well as chronic kidney disease and diabetes mellitus.

26 Apr 2011

JASN publishes positive results from pirfenidone study in diabetic nephropathy

Researchers at the University of California, San Diego School of Medicine, the National Institutes of Health and the Mayo Clinic have published promising results of a clinical study using an experimental anti-fibrotic and anti-inflammatory drug called pirfenidone to treat patients with diabetic nephropathy. Their study will be published in the April 21 issue of the Journal of the American Society of Nephrology.

22 Apr 2011

Elderly individuals with CKD more likely to suffer from heart disease

Chronic kidney disease is common and linked with heart disease in the very elderly, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

22 Apr 2011

DaVita re-designs its leading online kidney disease resource

DaVita Inc., a leading provider of kidney care services for those diagnosed with end stage renal disease and chronic kidney disease, today announced the redesign and launch of DaVita.com, the leading online resource for information about kidney disease.

19 Apr 2011

Abbott submits ARCHITECT 25-OH Vitamin D assay application to FDA for clearance

According to a recent report from the U.S. Centers for Disease Control and Prevention, a third of Americans have vitamin D levels that are either inadequate or deficient. While many people know that vitamin D is necessary to help the body absorb calcium, which helps create strong bones and muscles, many don't know that insufficient levels of this important vitamin may lead to other health problems.

16 Apr 2011

Chronic Kidney Disease News and Research

Latest Chronic Kidney Disease News and Research

Phosphate regulating hormone associated with increased risk of kidney failure and death among CKD patients

High FGF-23 hormone levels linked to increased risk of end-stage renal disease and death

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

Study reveals positive impact of Soliris on long-term outcomes in PNH patients

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Promising results from KAI-4169 program for CKD-MBD presented at ENDO 2011

Higher than IOM recommended Vitamin D levels required for optimizing osteoporosis, low BMD therapy

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Stem cells from kidneys - World first from Australian scientists

DaVita completes nationwide rollout of wireless Internet access at dialysis treatment clinics

FibroGen announces proof-of-principle for FG-4592 Phase 2 study in hemodialysis patients

Mediaplanet releases Kidney Health report to targeted markets in USA

DVA is now DaVita Labs

Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients

Ramipril can effectively reduce risk of ESRD in obese patients

ACC/AHA release consensus document to help clinicians reduce risk of hypertension in older adults

JASN publishes positive results from pirfenidone study in diabetic nephropathy

Elderly individuals with CKD more likely to suffer from heart disease

DaVita re-designs its leading online kidney disease resource

Abbott submits ARCHITECT 25-OH Vitamin D assay application to FDA for clearance

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Chronic Kidney Disease News and Research

Latest Chronic Kidney Disease News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in